Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/GB05/000751

International filing date: 28 February 2005 (28.02.2005)

Document type: Certified copy of priority document

Document details: Country/Office: GB
Number: 0404487.1
Filing date: 28 February 2004 (28.02.2004)

Date of receipt at the International Bureau: 21 April 2005 (21.04.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)

PCT/GB 2005 / 0 0 0 7 5 1

PATENTS • DESIGNS • COPYRIGHT • TRADE MARKS
The Patent Office

INVESTOR IN PEOPLE

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed Andrew Gerrey

Dated 6 April 2005

Patents Form 1/77

Patents Act 1977
(Rule 16)

THE PATENT OFFICE
F
28 FEB 2004
NEWPORT

The Patent Office

01MAR04 E877084-5 D02866
P01/7700-0.00-0404487.1 CHE
UE

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

28 FEB 2004

The Patent Office

Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

1. Your reference — PROW / P29317GB

2. Patent application number *(The Patent Office will fill in this part)* — 0404487.1

3. Full name, address and postcode of the or of each applicant *(underline all surnames)*

Protherics Molecular Design Limited
The Heath Business and Technical Park
Runcorn
Cheshire
WA7 4QF
United Kingdom

Patents ADP number *(if you know it)* 07935026002

If the applicant is a corporate body, give the country/state of its incorporation — United Kingdom

4. Title of the invention

USE OF ENZYME

5. Name of your agent *(if you have one)*

"Address for service" in the United Kingdom to which all correspondence should be sent *(including the postcode)*

ERIC POTTER CLARKSON
PARK VIEW HOUSE
58 THE ROPEWALK
NOTTINGHAM
NG1 5DD

Patents ADP number *(if you know it)* **1305010** ✓

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and *(if you know it)* the or each application number

Country	Priority application number *(if you know it)*	Date of filing *(day / month / year)*

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application	Date of filing *(day / month / year)*

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? *(Answer 'Yes' if:*

a) *any applicant named in part 3 is not an inventor; or*
b) *there is an inventor who is not named as an applicant, or*
c) *any named applicant is a corporate body. See note (d))*

YES

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form	
Description	47
Claims(s)	13
Abstract	1
Drawing(s)	2 + 2 &V

10. If you are also filing in any of the following, state how many against each item.

Priority Documents	0
Translations of priority documents	0
Statement of inventorship and right to grant of a patent *(Patents Form 7/77)*	NO
Request for preliminary examination and search *(Patents Form 9/77)*	YES
Request for substantive examination *(Patents Form 10/77)*	NO
Any other documents *(please specify)*	

11. I/We request the grant of a patent on the basis of this application.

Signature Eric Potter Clarkson — Date 27 February 2004

ERIC POTTER CLARKSON

12. Name and daytime telephone number of person to contact in the United Kingdom **0115 9552211**

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

a) *If you need help to fill in this form or you have any questions, please contact the Patent Office on 01645 500505.*
b) *Write your answers in capital letters using black ink or you may type them.*
c) *If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.*
d) *If you have answered 'Yes' Patents Form 7/77 will need to be filed.*
e) *Once you have filled in the form you must remember to sign and date it.*
f) *For details of the fee and ways to pay please contact the Patent Office.*

FIGURE 1

```
  -1 MRPSIHRTAI AAVLATAFVA GTALAQKRDN VLFQAATDEQ PAVIKTLEKL   50
  51 VNIETGTGDA EGIAAAGNFL EAELKNLGFT VTRSKSAGLV VGDNIVGKIK  100
 101 GRGGKNLLLM SHMDTVYLKG ILAKAPFRVE GDKAYGPGIA DDKGGNAVIL  150
 151 HTLKLLKEYG VRDYGTITVL FNTDEEKGSF GSRDLIQEEA KLADYVLSFE  200
 201 PTSAGDEKLS LGTSGIAYVQ VNITGKASHA GAAPELGVNA LVEASDLVLR  250
 251 TMNIDDKAKN LRFNWTIAKA GNVSNIIPAS ATLNADVRYA RNEDFDAAMK  300
 301 TLEERAQQKK LPEADVKVIV TRGRPAFNAG EGGKKLVDKA VAYYKEAGGT  350
 351 LGVEERTGGG TDAAYAALSG KPVIESLGLP GFGYHSDKAE YVDISAIPRR  400
 401 LYMAARLIMD LGAGK                                      415
```

FIGURE 2



Tomudex
(IV)



Methotrexate
(X; prior art)



Edatrexate
(V)



Lometrexol
(VI)



ZD9331
(VII)



MTA
(VIII)



MDAM
(IX)

USE OF ENZYME

The present invention relates to the uses of an enzyme having carboxypeptidase G activity, and in particular to its use in combating toxicity caused by antifolate compounds.

Natural folates are used by cells in the folate pathway to synthesise DNA, RNA and in protein synthesis, and are therefore essential dietary requirements (Jolivet 1983, Pinedo 1976, Goldman 1975).

The three enzymes in the folate pathway most studied as targets for antifolate drugs are dihydrofolate reductase (DHFR), thymidylate synthase (TS) and glycinamide ribonucleotide formyltransferase (GARFT). DHFR and TS, along with serine hydroxymethyltransferase (SHMT), comprise the three enzymes of the thymidylate cycle. SHMT catalyzes the conversion of serine to glycine with the formation of methylenetetrahydrofolic acid (MTHF). MTHF, under the influence of TS, donates its methylene group to deoxyuridylic acid to form thymidylate, an essential component of DNA. Importantly, in the TS reaction, tetrahydrofolate (THF) supplies reducing equivalents for the conversion of the methylene group of MTHF to the methyl group of thymidylate (dTMP). Thus, for every molecule of dTMP formed, a molecule of THF is converted to dihydrofolate (DHF). DHF must be converted back to THF so that TS cycle should continue producing dTMP. This reaction is catalyzed by DHFR which utilizes NADPH as the reductant. DHFR also catalyzes the conversion of folic acid to DHF.

GARFT catalyzes the third in the series of ten reactions required for *de novo* purine biosynthesis, the conversion of glycinamide ribonucleotide to formylglycinamide ribonucleotide utilizing 10-formylTHF as the formyl

donor. GARFT occurs in mammals as a trifunctional protein which catalyzes the second and the fifth steps on this pathway in addition to the third. GARFT activity resides in the carboxy-terminal portion of this tri-functional protein. *De novo* purine biosynthesis leads to the formation of inosine monophosphate, the precursor of ATP and GTP necessary for RNA formation and of dATP and dGTP necessary for DNA formation.

Inhibition of DHFR leads to a deficiency of dTMP because DHF cannot be recycled for use in the TS reaction. This in turn leads to deficient DNA synthesis, DNA breakdown and cell death. Direct inhibition of TS likewise leads to a deficiency of dTMP and cell death. Direct inhibition of GARFT leads to depletion of purine nucleotides, which also leads to cell death, but the degree of cell kill is generally less than that produced by an equally growth-inhibitory concentration of a TS inhibitor (Kisliuk *et al*, 2003).

Methotrexate (MTX), a synthetic folate analogue, has been in clinical use since 1948 (Bleyer 1978) and is an important component of various chemotherapeutic regimens used for the treatment of patients with neoplastic diseases. The cytotoxic effects of both MTX and its active metabolites is through the inhibition of DHFR leading to inhibition of DNA synthesis, repair and cellular replication. Actively proliferating tissue, such as malignant cells, are in general more sensitive to this cellular interference by MTX. In addition, MTX has immunomodulating effects and is used in the treatment of a number of other diseases, such as rheumatoid arthritis (RA), multiple sclerosis (MS) and psoriasis. Application of high doses of MTX, usually administered as a prolonged infusion, is nowadays frequently used in patients with Non-Hodgkin's Lymphoma (NHL), acute lymphoblastic leukemia (ALL) or soft tissue tumours such as osteosarcoma.

Although actively proliferating malignant tissues are most sensitive to MTX, MTX can still be toxic to healthy cells in a dose and time dependent manner through two principle mechanisms. The first is common to all antifolates. This mechanism is through the inhibition of DNA synthesis and cellular metabolism, which is the underlying mechanism that is responsible for MTX's cytotoxic anti-cancer action. The risk of significant toxicity to healthy cells correlates with increasing doses of MTX and the time of exposure. MTX therapy is associated with a spectrum of toxicities, with myelosuppression, mucositis, acute hepatitis and nephrotoxicity being the most frequent and serious complications (Bleyer 1978). Additional toxicities seen with high dose therapy are acute desquamative dermatitis, B-lymphocyte dysfunction, and neurological effects. As discussed below, similar common toxicities are also caused by other antifolate drugs, although they have generally been administered at lower doses than MTX.

The second mechanism is MTX induced renal tubular obstruction and consequent renal dysfunction (MTX nephrotoxicity). MTX is metabolised by liver aldehyde oxidase to 7-hydroxy-MTX. The aqueous solubility of 7-hydroxy-MTX is 3 to 5 times lower than that of the parent compound and, under certain conditions, is known to precipitate in the renal tubules which is thought to be a principal mechanism in the pathogenesis of the MTX nephrotoxicity (Kintzel 2001, Condit 1969). Normal kidney function will accommodate removal of a particular load in a given time, thereafter accumulation and damage will ensue. If a patient receiving MTX develops nephrotoxicity leading to impaired elimination of MTX, a self-perpetuating cycle is initiated of reduced elimination, sustained high plasma MTX levels and subsequent exacerbation of both non-renal toxicity and progression of renal tubular damage, eventually leading to the death of the patient (although mortality can occur even in the absence of total renal failure).

Renal toxicity has been recorded with other antifolate compounds, but this may not be due to an analogous 7-hydroxylation of the compound. 7-OH-MTX toxicity occurs at high MTX doses, while the typical administered doses of the further antifolates described herein would only be considered to be 'intermediate' doses for MTX.

As a result of fatal outcomes from MTX toxicity, protection measures are routinely included in MTX therapeutic regimes:

1. Leucovorin rescue: Leucovorin calcium is the calcium salt of 5-formyl tetrahydrofolic acid (also known as folinic acid/folinate), the DHFR metabolite of folic acid and an essential coenzyme for nucleic acid synthesis and is not inhibited by MTX (Immunex Corporation 2001). As a result, leucovorin calcium is able to rescue MTX inhibited cells. However, at high MTX concentrations, leucovorin calcium may fail to prevent systemic toxicities (Goldman, 1975; Pinedo, 1976). Reversal of MTX by leucovorin calcium is competitive, with relatively higher concentrations required as the MTX concentration increases. When concentrations of MTX reach 100 μM, even ten-fold higher leucovorin calcium concentrations (1,000 μM) are unable to protect bone marrow cells from toxicity (Pinedo, 1976).

2. Hydration and alkalinisation is required to enhance the solubility of MTX and thus prevent MTX nephrotoxicity, which can lead to renal impairment.

With these measures, the incidence of life-threatening MTX toxicity may be lowered to around 1.5%. However, despite these precautions, prolonged MTX-clearance due to drug-related renal insufficiency may develop and

lead to severe and life-threatening systemic toxicities, such as myelosuppression, mucositis, hepatitis and dermatitis. In the past, several attempts have been made to ameliorate systemic MTX toxicity in such patients. First, haemo- or peritoneal dialysis may enhance MTX clearance but usually result in only small and transient decreases of toxic serum MTX levels. Second, administration of thymidine or an intensified leucovorin rescue may lower systemic MTX toxicity but does not enhance MTX excretion.

MTX remains, with the limited exceptions, the only antifolate anticancer agent in clinical use to this date. Because of the relative safety and utility of MTX, considerable effort has been invested in attempting to design more therapeutically selective antifolates or antifolates with a wider tumor spectrum. Initially, the design was based on the burgeoning knowledge of folate-dependent pathways and the determinants of the mechanism of action of MTX. These determinants include transport, the tight-binding inhibition of its target, DHFR, and metabolism of MTX to poly-γ-glutamate (Glu_n) metabolites. These early studies led to the development of other antifolate inhibitors of two types: (1) "classical" analogs that use the same cellular transport systems as MTX and are also metabolized to Glu_n; and (2) "nonclassical" (ie, lipophilic) analogs that do not require transport systems and that are not metabolized to Glu_n. Although several of these analogs have undergone clinical trial, none has yet proved superior to MTX (McGuire, 2003).

Detailed examination of the mechanisms of cytotoxicity and selectivity of MTX showed that inhibition of both dTMP synthesis and *de novo* purine synthesis, secondary to DHFR inhibition, led to DNA synthesis inhibition and subsequent cell death; inhibition of other folate-dependent pathways did

not appear necessary for cell death. Further studies showed that the contribution of inhibition of dTMP or purine synthesis to cell death varied in different cell types. These data suggested that inhibition of one of these pathways individually might (at least in some cases) be therapeutically superior to the dual inhibition induced by MTX. Thus in rational design and in structure-based design studies, two new classes of antifolate enzyme inhibitors were elaborated: direct inhibitors of TS and direct inhibitors of one or both of the two folate-dependent enzymes of *de novo* purine synthesis. Members of each class included both classical and nonclassical types. After preclinical evaluation, several of these have moved into clinical trials. To date only two new antifolate compounds have been approved for routine use; Tomudex (D1694, raltitrexed) is currently approved in Europe for the treatment of colon cancer and Pemetrexed (Alimta) has been approved in the US for pleural mesothelioma. This still represents a step forward for antifolates since, for example, MTX is ineffective against colon cancer.

Antifolate development continues. Based on the immense body of knowledge now extant on antifolates, specific aspects of the mechanism of action have been the focus. Newer antifolates have been described that inhibit more than one pathway in folate metabolism, that have improved delivery, or that inhibit other targets in folate metabolism. These new analogs are in various stages of preclinical and clinical development (McGuire, 2003; Kisliuk, 2003; Purcell & Ettinger, 2003; each of which is incorporated by reference in this entirety).

As with MTX, one major drawback to the clinical use of the newer antifolate drugs is an unacceptable level of toxicity. The ability to degrade these antifolate drugs rapidly *in vivo* would have two major clinical

advantages. Firstly, it would minimize toxicity caused by the antifolate drugs. It also allows a higher dose of the antifolate compounds to be administered, potentially leading to a greater clinical effect. The lower toxicity and higher efficacy may be sufficient to realise the clinical promise of a number of drugs that have not progressed through clinical trials. Furthermore, as toxicity associated with antifolate drugs is normally duration-related rather than dose-related, the ability to rapidly remove excess free drug at a given time point may be therapeutically very useful.

Carboxypeptidase G_2 (CPG_2) is a folate-degrading enzyme from Pseudomonas sp. strain RS-16 (now reclassified as *Variovorax paradoxus*) and is a zinc-dependent dimeric protein of 83,000 – 84,000 Dalton (Kalghati 1981; Chabner 1972; McCullough 1971; Minton1983; and Sherwood 1985). CPG_2 has a relatively restricted specificity and hydrolyses the C-terminal glutamic acid residue of folic acid, poly-glutamyl derivatives of folic acid, folate analogues, eg methotrexate, and sub-fragments of folic acid eg, p-aminobenzoyl glutamate (Minton *et al*, 1983). To date carboxypeptidase enzymes have only been characterised in a small number of Pseudomonas sp. and can be separated on the basis of their substrate affinities for folate and its analogues (Kalghatgi and Bertino, 1981).

Sherwood *et al* (1985) have previously reported that CPG_2 follows Michaelis-Menten kinetics with K_m values of 4μM for folate, 8μM for MTX, 34μM for 5-methyl THF, and 120μM for 5-formyl THF (leucovorin). CPG_2 cleaves methotrexate (MTX) into inactive metabolites, 4-deoxy-4-amino-N^{10}-methylpteroic acid (DAMPA) and glutamate, and thus may provide an alternative route of MTX elimination particularly in patients who develop renal dysfunction due to MTX nephrotoxicity (Adamson, 1991; Mohty, 2000; von Poblozki, 2000; Widemann, 2000).

Para-aminobenzoyl glutamate is a substrate of CPG_2, as are a number of mustard prodrugs based on p-aminobenzoyl glutamate (Springer *et al* (1995); Dowell *et al* (1996)). However, there have been no reported studies that have attempted to assess whether any of the new antifolate drugs are substrates for CPG_2 cleavage. Prior to the present invention, it was not known whether any folate compounds other than folic acid, MTX, 5-methyl THF, and 5-formyl THF were substrates for CPG_2. It was not known, and could not predicted, whether any of the new generation of antifolate drugs are substrates for CPG_2 cleavage.

We have now shown that Tomudex is a substrate for CPG_2 and has a K_m of 7.8μM and a k_{cat} of 24/s as measured by spectrophotometric assay. All the known substrates for CPG_2 have a benzene ring at a position equivalent to position Ar of Formula I, see below. Furthermore, the mustard prodrug p-aminobenzoyl glutamate derivatives assessed by Springer *et al* (1995) suggest that modifications on this benzene ring may be detrimental to carboxypeptidase activity. Tomudex, by contrast, has a thiophene ring at this position which is not an isosteric replacement for the benzene ring. Thus Tomudex, along with other antifolates with a thiophene at this position such as the GARFT inhibitors LY309987, AG2034 and AG2037 (McGuire, 2003) would not have been predicted to be substrates of CPG_2.

We also believe that other antifolates including ZD9331 that have the structural group $-CH_2C{\equiv}CH$ subsisting from the N in the para position to the benzene ring (ie antifolates in which X represents $-CH_2NR^{7b}-$ wherein R^{7b} represents $-CH_2C{\equiv}CH$ according to Formula I) are also substrates of CPG_2. All other known folate substrates of CPG_2 are either unsubstituted or have methyl or ethyl groups at this position. Cleavage by CPG_2 of antifolates that

have a substituent with a triple bond, eg $-CH_2C{\equiv}CH$, at this position is therefore totally unexpected.

Similarly, we also believe that other antifolates including Edatrexate, Lometrexol, Pemetrexed (MTA) and MDAM that lack a nitrogen, amino group or substituted amino group (at a position equivalent to position X in Formula I) in the para position to the benzene ring (at a position equivalent to position Ar in Formula I) are also substrates for CPG_2 cleavage. Cleavage by CPG_2 of such antifolates is totally unexpected.

Antifolate compounds are useful in treating a range of medical conditions, particularly cancers, and being able to combat toxicity associated with these compounds will significantly increase their therapeutic value.

A first aspect of the invention provides a method of combating toxicity caused by an antifolate compound of Formula I,



I

wherein

R^1 represents NH_2, OH or CH_3;

R^2 represents NH_2 or $C_{1\text{-}4}$ alkyl;

the group B represents a structural fragment of Formula Ia, Ib, Ic, Id or Ie,



Ia



Ib



Ic



Id



Ie

in which groups the dashed lines indicate the point of ring fusion with the pyrimidinyl ring and the wavy lines indicate the point of attachment of the structural fragments to the group X;

R^{5a} to R^{5e} independently represent H or C_{1-4} alkyl;

A^1 represents $C(R^{6a})$ or N;

A^2 represents CH or N;

A^3 represents $C(H)R^{6b}$, NR^{6c} or S;

A^4 and A^5 independently represent CH_2, NH, O or S;

the group B^1-B^2 represents CH-CH or C=C;

R^{6a} to R^{6c} independently represent H or C_{1-4} alkyl, or R^{6c} represents $C(O)R^{6d}$, or R^{6c}, together with R^{7b} represents C_{1-2} *n*-alkylene;

R^{6d} represents H or C_{1-4} alkyl;

X represents $-CH_2C(H)R^{7a}-$ or $-CH_2NR^{7b}-$ (in which latter two groups the CH_2 moiety is attached to the fused, pyrimidine-based heterocyclic group);

R^{7a} and R^{7b} independently represent H, C_{1-6} alkyl, C_{3-6} alkenyl or C_{3-6} alkynyl, or R^{7b}, together with R^{6c} represents C_{1-2} *n*-alkylene;

Ar represents a structural fragment of Formula IIa or IIb,



IIa IIb

wherein the wavy lines indicate the points of attachment of the structural fragments;

A^6 represents O or S;

R^{8a} and R^{8b} independently represent H or one or two substituents selected from halo, C_{1-4} alkyl and C_{1-4} alkoxy or R^{8a}, together with R^3, when R^{8a} is attached at a position that is *ortho-* to the position to which the moiety $C(O)NR^3$ is attached, represents C_{1-2} *n*-alkylene;

R^3 represents H or C_{1-4} alkyl, or R^3, together with R^{8a}, when the latter group is attached at a position that is *ortho-* to the position to which the moiety $C(O)NR^3$ is attached, represents C_{1-2} *n*-alkylene;

R^4 represents $-CH_2C(R^{9a})(R^{9b})-D$;

R^{9a} and R^{9b} independently represent H or C_{1-4} alkyl, or R^{9a} and R^{9b} together represent $=C(H)R^{10}$;

R^{10} represents H or C_{1-4} alkyl;

D represents C(O)OH, tetrazol-5-yl, $(CH_2)_{0-1}$-NHR^{11}, or, when R^{9a} and R^{9b} together represent $=C(H)R^{10}$, then D may also represent H, or D represents a structural fragment of Formula IIIa or IIIb,



IIIa



IIIb ;

wherein the wavy lines indicate the point of attachment of the structural fragments;

R^{11} represents H or $C(O)R^{12}$;

R^{12} represents H or phenyl substituted by C(O)OH and optionally substituted by one or two further substituents selected from halo, C_{1-4} alkyl and C_{1-4} alkoxy; and

alkyl, alkenyl and alkynyl groups, as well as the alkyl part of alkoxy groups, may be substituted by one or more halo atoms;

provided that when R^2 represents NH_2, Ar represents a structural fragment of Formula IIa in which R^{8a} represents H, R^3 represents H, R^{9a} and R^{9b} both represent H and D represents C(O)OH, then:

(a) when R^{7b} represents methyl and R^1 represents NH_2, then B does not represent a structural fragment of Formula Ia in which R^{5a} represents H and A^1 and A^2 both represent N; and

(b) when R^{7b} represents H and R^1 represents OH, then B does not represent

(i) a structural fragment of Formula Ia in which R^{5a} represents H and A^1 and A^2 both represent N, or

(ii) a structural fragment of Formula Ic in which R^{5c} represents H, A^3 represents NR^{6c}, R^{6c} represents methyl or CHO and A^4 represents NH,

in an individual who has been administered said compound, the method comprising administering to the individual an enzyme that has carboxypeptidase G activity.

For the avoidance of doubt, MTX is not a compound of Formula I as defined above.

The term "halo", when used herein, includes fluoro, chloro, bromo and iodo.

Compounds of Formula I may exhibit tautomerism. In particular, compounds of Formula I in which R^1 represents OH may alternatively be depicted as follows.



All tautomeric forms and mixtures thereof are included within the scope of the invention.

Compounds of Formula I that may be mentioned include the following.

(1) Compounds of Formula I in which Ar represents a structural fragment of Formula IIb when X represents $-CH_2NR^{7b}-$ and B represents a structural fragment of Formula Ia in which A^1 and A^2 both represent N or a structural fragment of Formula Ic.

(2) Compounds of Formula I in which Ar represents a structural fragment of Formula IIb when X represents $-CH_2NR^{7b}-$.

(3) Compounds of Formula I in which Ar represents a structural fragment of Formula IIb.

(4) Compounds of Formula I in which X represents $-CH_2C(H)R^{7a}-$.

(5) Compounds of Formula I in which D represents tetrazol-5-yl, $(CH_2)_{0-1}$-NHR^{11}, or, when R^{9a} and R^{9b} together represent $=C(H)R^{10}$, then D may also represent H, or D represents a structural fragment of Formula IIIa or IIIb.

(6) Compounds of Formula I in which R^{6b}, together with R^{7b}, represents C_{1-2} *n*-alkylene and the group B represents a structural fragment of Formula Ic, Id or Ie, or a structural fragment of Formula Ia in which A^1 and/or A^2 represents CH.

(7) Compounds of Formula I in which the group B represents a structural fragment of Formula Id or Ie, or a structural fragment of Formula Ia in which A^1 and A^2 both represent CH.

(8) Compounds of Formula I in which R^1 represents OH and R^{7b} represents C_{1-6} alkyl, C_{3-6} alkenyl or C_{3-6} alkynyl, or R^{7b}, together with R^{6c} represents C_{1-2} *n*-alkylene.

(9) Compounds of Formula I in which R^{8a} represents one or two substituents selected from halo, C_{1-4} alkyl and C_{1-4} alkoxy, or R^{8a}, together with R^3, when R^{8a} is attached at a position that is *ortho*- to the position to which the moiety $C(O)NR^3$ is attached, represents C_{1-2} *n*-alkylene.

(10) Compounds of Formula I in which R^{8a}, together with R^3, when R^{8a} is attached at a position that is *ortho*- to the position to which the moiety $C(O)NR^3$ is attached, represents C_{1-2} *n*-alkylene.

Other compounds of Formula I that may be mentioned include those in which:

R^1 represents NH_2 or, particularly, OH;

R^2 represents NH_2 or methyl;

the group B represents a structural fragment of Formula Ia, Ic or Id;

A^1 and A^2 both represent N or, particularly, both represent CH;

R^{5a}, R^{5c} and R^{5d} independently represent H or, when A^1 and A^2 both represent CH, R^{5a} may also represent methyl;

A^3 represents CH_2;

A^4 and A^5 independently represent NH;

the group B^1-B^2 represents CH-CH;

R^{7a} represents H, methyl or ethyl;

R^{7b} represents methyl or -$CH_2C{\equiv}CH$;

A^6 represents S;

R^{8a} represents halo (e.g. fluoro) or, particularly, H;

R^{8b} represents H;

R^3 represents H;

R^{9a} and R^{9b} both represent H or R^{9a} and R^{9b} together represent $=CH_2$;

R^{11} represents phenyl *ortho*-substituted by C(O)OH.

Still further compounds of Formula I that may be mentioned include those in which:

R^2 represents methyl;

the group B represents a structural fragment of Formula Ia;

R^{5a} represents H;

X represents -CH_2NR^{7b}-;

R^{7b} represents methyl;

Ar represents a structural fragment of Formula IIb;

D represents C(O)OH;

R^{9a} and R^{9b} both represent H.

In an embodiment, the compound of Formula I is one in which Ar represents a structural fragment of formula IIb and A^6 represents S (ie Ar represents a

2,6-thienyl group). Suitable compounds include Tomudex (Formula IV), LY309987, AG2034 and AG2037. Tomudex is most preferred.

In another embodiment, the compound of Formula I is one in which X represents $-CH_2C(H)R^{7a}-$ and Ar represents a structural fragment of Formula IIa (ie the compound is one in which X does not have a nitrogen para to the benzene ring of Formula IIa). Suitable compounds include Edatrexate (Formula V), Lometrexol (Formula VI), MTA/Pemetrexed (Formula VIII) and MDAM (Formula IX).

In another embodiment, the compound of Formula I is one in which X represents $-CH_2NR^{7b}-$ wherein R^{7b} represents $-CH_2C{\equiv}CH$. Suitable compounds include ZD9331 (Formula VII) and CB3717.

By "an enzyme that has carboxypeptidase G activity" we include the meaning of an enzyme that hydrolyses the C-terminal L-glutamic acid residue from folic acid, folate analogues, and sub-fragments of folic acid eg, p-aminobenzoyl glutamate.

Preferably, the enzyme that has carboxypeptidase G activity is carboxypeptidase G_2 (CPG_2), EC number 3.4.22.12.

The sequence of the gene encoding CPG_2 and the CPG_2 amino acid sequence can be found in GenBank Accession Nos. M12599 and AAA62842 and in Minton *et al* (*Gene* 31(1-3), 31-38 (1984)), Minton and Clarke (*J. Mol. Appl. Genet.* 3(1), 26-35 (1985)); and Chambers *et al* (*Appl. Microbiol. Biotechnol.* 29, 572-578 (1998)) and the amino acid sequence is listed in Figure 1.

In an embodiment the enzyme that has carboxypeptidase G activity may be a derivative of CPG_2 that has carboxypeptidase G activity. By a "derivative" of CPG_2 we include a fragment, variant, modification or fusion of CPG_2, or combinations thereof, which has carboxypeptidase G activity.

The derivatives may be made using protein chemistry techniques for example using partial proteolysis (either exolytically or endolytically), or by *de novo* synthesis. Alternatively, the derivatives may be made by recombinant DNA technology. Suitable techniques for cloning, manipulation, modification and expression of nucleic acids, and purification of expressed proteins, are well known in the art and are described for example in Sambrook *et al* (2001) "*Molecular Cloning, a Laboratory Manual*", 3rd edition, Sambrook *et al* (eds), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, USA, incorporated herein by reference.

By "fragment" of CPG_2 we mean any portion of the full length enzyme that has carboxypeptidase G activity. Typically, the fragment has at least 30% of the carboxypeptidase G activity of CPG_2. It is more preferred if the fragment has at least 50%, preferably at least 70% and more preferably at least 90% of the activity of CPG_2. Most preferably, the fragment has 100% or more of the carboxypeptidase G activity of CPG_2.

The carboxypeptidase G activity of a derivative of CPG_2 can readily be determined by a person of skill in the art using the enzyme assay described on page 448 of Sherwood *et al* (1985). The entire disclosure of Sherwood *et al* (1985) is incorporated herein by reference.

A "variant" of CPG_2 refers to CPG_2 that has been altered by an amino acid insertion, deletion and/or substitution, either conservative or non-

conservative, at one or more positions. By "conservative substitutions" is intended combinations such as Gly, Ala; Val, Ile, Leu; Asp, Glu; Asn, Gln; Ser, Thr; Lys, Arg; and Phe, Tyr. Such modifications may be made using the methods of protein engineering and site-directed mutagenesis, as described in Sambrook *et al 2001, supra.*

For example, it may be advantageous to modify one or more residues of one or both of the active site of the enzyme. Such variants may beneficially alter the specificity or activity of the enzyme. The crystal structure of CPG_2 was published by Rowsell *et al* (1997) and identifies the active sites of the enzyme. In other embodiments, it may be advantageous not to modify residues in the active sites. Sequence variants, typically outside the active sites, may protect the enzyme from *in vivo* metabolism or decrease antigenicity. Additionally, it may be advantageous to add one or more Cys residues to allow disulphide bonds to be formed.

Preferably, the variant of CPG_2 has at least 70% sequence identity with SEQ ID No: 1. It is more preferred if variant CPG_2 has at least 80%, preferably at least 85% and more preferably at least 90% sequence identity with SEQ ID No: 1. Most preferably, the variant CPG_2 has 91 or 92 or 93 or 94 or 95 or 96 or 97 or 98 or 99% or more sequence identity with SEQ ID No: 1.

The percent sequence identity between two polypeptides may be determined using suitable computer programs, for example the GAP program of the University of Wisconsin Genetic Computing Group and it will be appreciated that percent identity is calculated in relation to polypeptides whose sequence has been aligned optimally.

The alignment may alternatively be carried out using the Clustal W program (Thompson *et al.*, (1994) *Nucleic Acids Res* **22**, 4673-80). The parameters used may be as follows:

Fast pairwise alignment parameters: K-tuple(word) size; 1, window size; 5, gap penalty; 3, number of top diagonals; 5. Scoring method: x percent.

Multiple alignment parameters: gap open penalty; 10, gap extension penalty; 0.05.

Scoring matrix: BLOSUM.

Preferably, the variant of CPG_2, or a fragment of the variant, retains at least 30% of the carboxypeptidase G activity of CPG_2. It is more preferred if variant CPG_2 has at least 50%, preferably at least 70% and more preferably at least 90% of the activity of CPG_2. Most preferably, the variant of CPG_2 has 100% or more of the carboxypeptidase G activity of CPG_2.

Variants of CPG_2 with carboxypeptidase G activity have been described (US patent application no. 2004/0014187).

In an embodiment, the variant of CPG_2 has a substitution at one or more of the Asn residues at positions 222, 264 and 272 which are N-glycosylation sites. Preferably, Asn 222 is substituted with Gln; Asn 264 is substituted with Thr or Ser, most preferably Ser; and Asn 272 is substituted with Gln, independently or in combination. The most preferred combination of substitutions has Gln at positions 222 and 272 and Ser at residue 264. This QSQ motif results in a high catalytic activity and a low K_m for MTX (US 2004/0014187).

A "modification" of CPG_2 refers to CPG_2 in which one or more of the amino acid residues has been chemically modified. Such modifications include forming salts with acids or bases, especially physiologically acceptable organic or inorganic acids and bases, forming an ester or amide of a terminal carboxyl group, attaching amino acid protecting groups such as N-t-butoxycarbonyl and glycosylation. Such modifications may protect the enzyme from *in vivo* metabolism or decrease antigenicity. The CPG_2 may be present as single copies or as multiples, for example tandem repeats.

The invention also includes a fusion of CPG_2, or a fragment or variant thereof which has carboxypeptidase G activity, to another compound. Preferably, the fusion retains at least 30% of the activity of CPG_2. It is more preferred if the fusion has at least 50%, preferably at least 70% and more preferably at least 90% of the activity of CPG_2. Most preferably, the fusion has 100% or more of the carboxypeptidase G activity of CPG_2.

The invention may be used to alleviate symptoms of toxicity caused by the antifolate compound in an individual (ie palliative use), or may be used to reduce the severity of the toxicity in an individual, or may be used to treat toxicity in an individual, or may be used prophylactically to prevent toxicity in an individual. Thus, by "combating toxicity" we include the meaning of treating, reducing or preventing toxicity caused by the antifolate compound or alleviating the symptoms of it.

The enzyme that has carboxypeptidase G activity typically acts to combat toxicity caused by the antifolate compound by rapidly lowering plasma levels of the drug, thereby reducing the duration of exposure of normal tissues to the drug and preventing longer-term uptake.

Whether or not a particular patient is one who is expected to benefit from treatment may be determined by the physician.

By preventing toxicity we include the meaning of treating a patient at risk of toxicity, for example due to high levels and/or delayed elimination of the antifolate compound. Any patient who has been administered the antifolate compound may be considered to be at risk of toxicity caused by it.

In an embodiment, the individual at risk of toxicity may be one who has been administered the antifolate compound and who has not been tested for the presence of a clinical marker of toxicity caused by the antifolate compound.

In another embodiment, the individual at risk of toxicity may be one who has been administered the antifolate compound and has one or more clinical markers of toxicity caused by it.

Thus in an embodiment, the method may comprise the prior step of determining whether the individual who has been administered the antifolate compound has a clinical marker of toxicity caused by the antifolate compound.

In an embodiment, the clinical marker of toxicity caused by the antifolate compound may be a level of the compound, such as a plasma level, greater than a predetermined level at a given time after administration of the compound. The predetermined plasma level of the antifolate compound indicating toxicity may be 0.1 or 0.2 or 0.3 or 0.4 or 0.5 or 0.6 or 0.7 or 0.8 or 0.9 μmole per litre, or 1 or 2 or 3 or 4 or 5 μmole or more per litre at 24

hours after administration of the antifolate compound, or at 48, or 72 or 96 or 120 hours, or more, after administration of the antifolate compound.

Thus in another embodiment, the method may comprise the prior step of determining the level of the antifolate compound in the individual at a given time after administration of the compound to the individual, such as at 24 or 48, or 72 or 96 or 120 hours, or more, after administration of the antifolate compound.

The invention includes administering an enzyme that has carboxypeptidase G activity to an individual who has been administered an antifolate compound of Formula I as defined above, whether or not the individual has any symptoms of toxicity caused by the compound.

In an embodiment, it may be preferred to administer the enzyme to every individual who has been administered an antifolate compound of Formula I, for example, at a given time after administration of the compound of Formula I.

Thus the invention can be considered to be an *in vivo* method of cleaving an antifolate compound of Formula I as defined above.

In another embodiment, the individual at risk of toxicity may be one who has been administered the antifolate compound and has one or more clinical symptoms of toxicity caused by it.

Thus in an embodiment, the method may comprise the prior step of determining whether the individual who has been administered the antifolate compound has a clinical symptom of toxicity caused by the antifolate

compound.

Symptoms of toxicity for various of the antifolate compounds of Formula I as defined above are well known (reviewed by Purcell & Ettinger, 2003). For example, toxicities for Edatrexate include mucositis, myelosuppression and leukopaenia; toxicities for raltitrexed include mild mucositis, myelosuppression, neutropaenia, mild anaemia, dehydration, diarrhoea, nausea, asthenia and hepatotoxicity (Tsavaris *et al*, 2002; Massacesi *et al*, 2003); toxicities for Pemetrexed include, mucositis, myelosuppression, thrombocytopaenia, neutropaenia, anaemia, nausea and diarrhoea, although somewhat reduced by supplementation with folic acid and vitamin B_{12}, skin rash, fatigue and stomatitis (Martin *et al*, 2003); dose limiting toxicities for ZD9331 include neutropaenia, thrombocytopaenia and rash; and toxicities for MDAM include moderately severe nausea, vomiting, diarrhea, anorexia and fatigue, stomatitis, thrombocytopaenia and hyperbilirubinaemia (Johansen *et al*, 2003).

The individual is typically administered the enzyme that has carboxypeptidase G activity between about 24 and 48 hours after being administered the antifolate compound. Alternatively, the individual may be administered the enzyme between about 12 and 24 hours or between about 48 and 72 hours, or between about 72 and 96 hours, or between about 96 and 120 hours, or more, after being administered the antifolate compound.

The individual may be administered the enzyme that has carboxypeptidase G activity about 6 hours, or about 12 hours, or about 18 hours, or about 24 hours, or about 30 hours, or about 36 hours, or about 42 hours, or about 48 hours, or about 54 hours, or about 60 hours, or about 72 hours, or about 84

hours, or about 96 hours, or about 108 hours, or about 120 hours, or more, after being administered the antifolate compound.

It is appreciated that if the antifolate compound has been administered to the individual in error, the enzyme that has carboxypeptidase G activity is preferably administered as soon as possible once the error is noticed in order to combat toxicity caused by it. Similarly, if the individual has a clinical marker of toxicity caused by the antifolate compound, or a clinical symptom of toxicity caused by the antifolate compound, it may also be preferable to administer the enzyme as soon as possible.

The maximum tolerated dose for Tomudex on a 3-weekly schedule was found to be 3.5 to 4.5 mg/m^2 in adults and 6 mg/m^2 in a paediatric population (Clarke *et al*, 2000). A dose of 600 mg/m^2 of Pemetrexed administered every 3 weeks led to high but manageable levels of toxicity (Martin *et al*, 2003). A dose of 300 mg/m^2 of MDAM per day for 5 days every three weeks also led to high but manageable levels of toxicity, and a dose of 240 mg/m^2 was recommended (Johansen *et al*, 2003). The maximum tolerated dose of Edatrexate was found to be 3750 mg/m^2, however, because of the occurrence of leukoencephalopathy in one patient, high dose Edatrexate treatment was not recommended (Pisters *et al*, 1996). In each of these case, the subsequent administration of an enzyme that has carboxypeptidase G activity followed by degradation of antifolate compound, can increase the maximum tolerated dose of the antifolate compound thus increasing the efficacy of the drug and minimising any side effects.

The invention thus includes administering to an individual in need thereof, as described herein, a high dose of an antifolate compound of Formula I,

such as 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or more times the above doses, and subsequently administering an enzyme that has carboxypeptidase G activity to the individual.

The invention thus includes administering to an adult individual a dose of Tomudex equivalent to about 5 or 6 or 7 or 8 or 9 or 10 or 15 or 20 or 25 or 30 or 40 or 50 mg/m^2 or more on a 3-weekly schedule, or administering to a child a dose of Tomudex equivalent to 7 or 8 or 9 or 10 or 15 or 20 or 25 or 30 or 40 or 50 mg/m^2 or more on a 3-weekly schedule, and subsequently administering an enzyme that has carboxypeptidase G activity to the individual.

The invention thus includes administering a dose of Pemetrexed equivalent to about 700 or 800 or 900 or 1000 mg/m^2 or 1.5 or 2 or 2.5 or 3 or 3.5 or 4 or 5 or 6 or 7 or 8 or 9 or 10 g/m^2 or more on a 3-weekly schedule, and subsequently administering an enzyme that has carboxypeptidase G activity to the individual.

The invention thus includes administering a dose of MDAM equivalent to about 400 or 500 or 600 or 700 or 800 or 900 or 1000 mg/m^2 or 1.5 or 2 or 2.5 or 3 or 3.5 or 4 or 5 or 6 or 7 or 8 or 9 or 10 g/m^2 or more per day for 5 days on a 3-weekly schedule, and subsequently administering an enzyme that has carboxypeptidase G activity to the individual.

The invention thus includes administering a dose of Edatrexate equivalent to about 4 or 5 or 6 or 7 or 8 or 9 or 10 or 15 or 20 or 25 g/m^2 or more, and subsequently administering an enzyme that has carboxypeptidase G activity to the individual.

The enzyme that has carboxypeptidase G activity or a formulation thereof may be administered by any conventional method including parenteral (eg subcutaneous or intramuscular) injection. The treatment may consist of a single dose or a plurality of doses over a period of time.

Most preferably, the enzyme that has carboxypeptidase G activity or a formulation thereof is administered intravenously.

In some circumstances the enzyme that has carboxypeptidase G activity or a formulation thereof may be administered intrathecally, typically when the antifolate compound of formual I has been administered intrathecally.

Studies in rhesus monkeys indicate that the half life of CPG_2 in plasma following intravenous administration is between 52 and 58 minutes. Following intrathecal administration to rhesus monkeys, CPG_2's half life in cerebrospinal fluid has been estimated at between 3.3 and 3.9 hours.

Whilst it is possible for the enzyme that has carboxypeptidase G activity to be administered alone, it is preferable to present it as a pharmaceutical formulation, together with one or more acceptable carriers. The carrier(s) must be "acceptable" in the sense of being compatible with the compound of the invention and not deleterious to the recipients thereof. Typically, the carriers will be water or saline which will be sterile and pyrogen free.

In a preferred embodiment, the enzyme that has carboxypeptidase G activity is stored as a freeze-dried powder ready to be made up as a solution for injection as required. Typically, the contents of a vial of freeze dried enzyme are reconstituted with sterile normal saline (0.9% w/v), immediately before use.

In a preferred embodiment, the formulation of the enzyme that has carboxypeptidase G activity also contains lactose as an inactive ingredient, except for patients with hypersensitivity to lactose.

Typically, the enzyme that has carboxypeptidase G activity is administered to the individual at a dose of about 50 Units per kg body weight (1 unit corresponds to the enzyme activity that cleaves 1 micromole of MTX per minute at 37°C) intravenously over 5 minutes.

It is appreciated that the enzyme can be administered at lower doses of about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40 or 45 Units per kg/body weight. It is also appreciated that the enzyme can be administered at higher doses of about 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150 or 200 or higher Units per kg/body weight.

The frequency, timing and dosage of administration of the enzyme that has carboxypeptidase G activity may be determined by the physician, using knowledge of the properties of the enzyme, the levels of the antifolate enzyme in the patient, and the degree of any symptoms of toxicity in the patient.

It is appreciated that proteins and peptides may be delivered using an injectable sustained-release drug delivery system. These are designed specifically to reduce the frequency of injections. An example of such a system is Nutropin Depot which encapsulates recombinant human growth hormone (rhGH) in biodegradable microspheres that, once injected, release rhGH slowly over a sustained period.

An alternative method of protein and peptide delivery is the ReGel injectable system that is thermo-sensitive. Below body temperature, ReGel is an injectable liquid while at body temperature it immediately forms a gel reservoir that slowly erodes and dissolves into known, safe, biodegradable polymers. The active drug is delivered over time as the biopolymers dissolve.

It is further appreciated that the individual may be administered a polynucleotide that encodes the enzyme that has carboxypeptidase G activity, leading to *in vivo* expression of the enzyme. Suitable vectors and methods are well known to a person of skill in the art.

The individual to be treated may be any individual who would benefit from such treatment. Typically and preferably the individual to be treated is a human. However, the methods of the invention may be used to treat mammals, such as the cows, horses, pigs, sheep, cats and dogs. Thus, the methods have uses in both human and veterinary medicine.

In an embodiment, the method of combating toxicity caused by an antifolate compound of Formula I as defined above further comprises administering a folate pathway rescue agent to the individual.

By "a folate pathway rescue agent" we include the meaning of an agent that can rescue the folate pathway which is blocked by the antifolate compound. The most commonly used folate pathway rescue agent is leucovorin, the calcium salt of 5-formyl tetrahydrofolic acid. Alternative rescue agents may include other salts of 5-formyl tetrahydrofolic acid, and thymidine itself. Typically, if the antifolate compound is an inhibitor of DHFR or of GARFT,

the folate pathway rescue agent is leucovorin, while if the antifolate compound is an inhibitor of TS, the folate pathway rescue agent is thymidine.

For example, it is known that Edatrexate is an inhibitor of DHFR, Lometrexol is an inhibitor of GARFT, and Tomudex, Nolatrexed and ZD9331 are known to be inhibitors of TS. Pemetrexed (MTA) is a multi-functional agent and inhibits DHFR, GARFT and TS (Kisliuk, 2003). Thus, the appropriate folate pathway rescue agent can readily be determined.

In an embodiment, the individual is administered the enzyme that has carboxypeptidase G activity prior to the folate pathway rescue agent. Alternatively, the individual may be administered the folate pathway rescue agent prior to the enzyme that has carboxypeptidase G activity. In yet another embodiment, the individual may be administered the folate pathway rescue agent and the enzyme that has carboxypeptidase G activity substantially simultaneously.

The antifolate compounds may be useful in treating a range of medical conditions, and being able to combat toxicity associated with these compounds increases their therapeutic value.

The invention includes a method of treating a disease selected from cancer, RA, MS, psoriasis, extrauterine pregnancy and graft vs. host disease, the method comprising administering an antifolate compound of Formula I as defined above to the individual, and subsequently administering to the individual an enzyme that has carboxypeptidase G activity.

The subsequent administration of the enzyme that has carboxypeptidase G activity is to combat toxicity caused by the antifolate compound as described above.

Thus the invention includes a method of treating a disease selected from cancer, RA, MS, psoriasis, extrauterine pregnancy and graft vs. host disease comprising administering an antifolate compound of Formula I as defined above to the individual, and combating toxicity caused by the antifolate compound as described above.

Cancers which can be treated by the antifolate compounds of Formula I, are well known to a person of skill in the art, some of which are discussed by McGuire (2003); Kisliuk (2003); and Purcell & Ettinger (2003), as well as in the specific references mentioned below.

The invention includes a method of treating cancer, the method comprising administering Tomudex to the individual, and combating toxicity caused by Tomudex by administering an enzyme that has carboxypeptidase G activity.

The cancer to be treated by administration of Tomudex may be cancer of the breast, ovary, colon/rectum, liver, prostate, pancreas or stomach, as well as non small cell lung cancer (NSCLC), malignant mesothelioma or carcinoma of unknown primary (Clarke *et al* (2000); Tsavaris *et al* (2002); Franchi *et al* (2003); and Massacesi *et al* (2003)).

The invention includes a method of treating cancer, the method comprising administering Edatrexate to the individual, and combating toxicity caused by Edatrexate by administering an enzyme that has carboxypeptidase G activity.

The cancer to be treated by administration of Edatrexate may be breast, lung, head and neck squamous cell carcinoma, NSCLC, non-Hodgkin's lymphoma, germ cell tumour, pleural mesothelioma or malignant fibrous histiocytoma (Kuriakose *et al* (2002); Dreicer *et al* (1997); Pisters *et al* (1996); and Meyers *et al* (1998-9)).

The invention includes a method of treating cancer, the method comprising administering ZD9331 to the individual, and combating toxicity caused by ZD9331 by administering an enzyme that has carboxypeptidase G activity.

The cancer to be treated by administration of ZD9331 may be ovarian, colorectal, gastric, small cell lung cancer, fallopian tube cancer, primary peritoneal cancer or lymphoma.

The invention includes a method of treating cancer, the method comprising administering Pemetrexed to the individual, and combating toxicity caused by Pemetrexed by administering an enzyme that has carboxypeptidase G activity.

The cancer to be treated by administration of Pemetrexed may be leukemia, mesothelioma, NSCLC, breast, colon, pancreas, kidney, bladder, gastrointestinal cancer, head and neck cancer, urothelial cancer or cervical carcinoma (Martin *et al* (2003); Thodtmann *et al* (2003); and Ettinger (2002)).

The invention includes a method of treating cancer, the method comprising administering Lometrexol to the individual, and combating toxicity caused

by Lometrexol by administering an enzyme that has carboxypeptidase G activity.

The cancer to be treated by administration of Lometrexol may be soft tissue sarcoma, NSCLC, breast, head and neck cancer or melanoma.

The invention also includes a method of treating cancer, the method comprising administering MDAM to the individual, and combating toxicity caused by MDAM by administering an enzyme that has carboxypeptidase G activity.

The cancer to be treated by administration of MDAM may be a solid tumor, such as colorectal tumour (Johansen, 2003).

A second aspect of the invention provides the use of an enzyme that has carboxypeptidase G activity in the preparation of a medicament for combating toxicity caused by an antifolate compound of Formula I as defined above in the first aspect of the invention.

Preferences regarding the antifolate compound of Formula I in this and subsequent aspects of the invention are as described above with respect to the first aspect of the invention

The invention includes use of an enzyme that has carboxypeptidase G activity for combating toxicity in an individual who has one of more clinical signs or markers of toxicity caused by said compound, as described above.

In an embodiment, the invention includes use of the enzyme that has carboxypeptidase G activity in the preparation of a medicament for

combating toxicity caused by an antifolate compound of Formula I as defined above in an individual who is administered a folate pathway rescue agent. The individual may be administered the folate pathway rescue agent prior to the medicament, or the individual may be administered the folate pathway rescue agent after the medicament, or the individual may be administered the folate pathway rescue agent and the medicament substantially simultaneously.

Preferences regarding the folate pathway rescue agent in this and subsequent aspects of the invention are as described above with respect to the first aspect of the invention

A third aspect of the invention provides the use of an antifolate compound of Formula I as defined above in the preparation of a medicament for combating a condition that is combatable by said antifolate compound in an individual who is subsequently administered an enzyme that has carboxypeptidase G activity.

In an embodiment, the individual is also administered a folate pathway rescue agent. The enzyme that has carboxypeptidase G activity may be administered before, after, or substantially simultaneously with the folate pathway rescue agent.

A fourth aspect of the invention provides the use of a folate pathway rescue agent in the preparation of a medicament for combating toxicity caused by an antifolate compound of Formula I as defined above in an individual who is administered an enzyme that has carboxypeptidase G activity. The individual may be administered the enzyme prior to the medicament, or the individual may be administered the enzyme after the medicament, or the

individual may be administered the enzyme and the medicament substantially simultaneously.

A fifth aspect of the invention provides the use of an enzyme that has carboxypeptidase G activity and a folate pathway rescue agent in the preparation of a medicament for combating toxicity caused by an antifolate compound of Formula I as defined above.

The invention includes the use as defined above in the second, third, fourth and fifth aspects of the invention for combating toxicity caused by an antifolate compound of Formula I in an individual who is being treated for a disease selected from cancer, RA, MS, psoriasis, extrauterine pregnancy and graft vs. host disease by administration of the antifolate compound, as detailed above.

A sixth aspect of the invention provides the use of an antifolate compound of Formula I as defined above in the preparation of a medicament for treating a condition selected from cancer, RA, MS, psoriasis, extrauterine pregnancy and graft vs. host disease in an individual who is subsequently administered an enzyme that has carboxypeptidase G activity.

In an embodiment, the invention includes the use of Tomudex in the preparation of a medicament for treating cancer in an individual who is administered an enzyme that has carboxypeptidase G activity. The invention also includes the use of an enzyme that has carboxypeptidase G activity in the preparation of a medicament for combating toxicity caused by Tomudex. Typically, the individual has been administered the Tomudex to treat cancer.

The cancer to be treated by administration of Tomudex may be cancer of the breast, ovary, colon/rectum, liver, prostate, pancreas or stomach, as well as NSCLC, malignant mesothelioma or carcinoma of unknown primary.

Similarly, cancers that can be treated by administration of a medicament containing Edatrexate, ZD9331, Pemetrexed, Lometrexol and MDAM are known in the art, and include those listed above.

The invention thus includes the use of an enzyme that has carboxypeptidase G activity in the preparation of a medicament for complementing the therapy of a disease selected from cancer, RA, MS, psoriasis, extrauterine pregnancy and graft vs. host disease that is being treated by administration of an antifolate compound of Formula I.

A seventh aspect of the invention provides an *ex vivo* method of cleaving a terminal L-glutamate moiety from a compound of Formula I as defined above, the method comprising contacting the compound with an enzyme that has carboxypeptidase G activity.

An eighth aspect of the invention provides a method of determining the rate and/or extent of cleavage of a compound of Formula I as defined above by an enzyme that has carboxypeptidase G activity, the method comprising:

providing a compound of Formula I,

contacting the compound of Formula I with an enzyme that has carboxypeptidase G activity under conditions such that cleavage of the compound can occur, and

monitoring the rate and/or extent of cleavage of the compound of Formula I over time.

In an embodiment, the providing step comprises providing a known amount or concentration of the compound of Formula I.

In an embodiment, the monitoring step comprises monitoring the amount and/or concentration of the compound of Formula I over time. Additionally or alternatively, the monitoring step comprises monitoring the amount and/or concentration of one or more break-down products of the compound of Formula I over time.

It is appreciated that the method of determining the rate and/or extent of cleavage can be performed *ex vivo*, or can be performed *in vivo*.

When the method is performed *in vivo* it can be used to monitor the level of the compound of Formula I that remains uncleaved after treatment with the enzyme that has carboxypeptidase G activity. Thus the method can be used to monitor the effectiveness of the enzyme that has carboxypeptidase G activity in combating toxicity associated with the compound of Formula I.

The method may further comprise determining whether an additional dose of the enzyme that has carboxypeptidase G activity is required in order to reduce the amount of the compound of Formula I to a predetermined level, typically a level which does not cause toxicity. The amount of enzyme to be administered in the additional dose may also be determined.

The method may therefore also comprise contacting the compound of Formula I with an additional dose of the enzyme that has carboxypeptidase G activity under conditions such that cleavage of the compound of Formula I can occur.

A ninth aspect of the invention provides a therapeutic system (or it may be termed a "kit of parts") consisting of or comprising an antifolate compound of Formula I as defined above and an enzyme that has carboxypeptidase G activity. Optionally, the therapeutic system may also contain a folate pathway rescue agent.

Preferably, the therapeutic system contains a preferred compound of Formula I as defined above in the first aspect of the invention. Still preferably, the therapeutic system contains carboxypeptidase G_2, or a derivative thereof that has carboxypeptidase G activity, as defined above in the first aspect of the invention. Preferred folate pathway rescue agents are also as defined in the first aspect of the invention. The therapeutic system or kit of parts may suitably contain both the compound of Formula I and the enzyme that has carboxypeptidase G activity, and optionally the folate pathway rescue agent, packaged and presented in a suitable formulation either for storage or for use. Thus, for example, the enzyme that has carboxypeptidase G activity may be a freeze-dried powder ready to be reconstituted as a solution for injection, or may already be reconstituted as a solution for injection. Typically, the compound of Formula I and the enzyme are for separate administration in a particular treatment regime, thus they are packaged or formulated separately. The enzyme and the folate pathway rescue agent may be administered together, and thus may be formulated for co-administration.

All of the documents referred to herein are incorporated herein, in their entirety, by reference.

The listing or discussion of a prior-published document in this specification should not necessarily be taken as an acknowledgement that the document is

part of the state of the art or is common general knowledge.

The invention will now be described in more detail by reference to the following figures and Examples.

Figure 1 is the amino acid sequence of CPG_2 (SEQ ID No: 1).

Figure 2 shows the chemical structure of six substrates of CPG_2. Tomudex (Formula IV), Edatrexate (Formula V), Lometrexol (Formula VI), ZD9331 (Formula VII), MTA (Formula VIII), MDAM (Formula IX) and Methotrexate (Formula X, prior art).

Example 1: Identification of new substrates for CPG_2

A: Tomudex (Formula IV)

Tomudex is a thymidilate synthase inhibitor (Astra Zeneca). Tomudex was contacted with CPG_2 *in vitro* and was found to a substrate of CPG_2 as described below.

Deglutamylation of Tomudex by CPG_2 was measured spectrophotometrically. A stock solution of 10mM Tomudex in 100mM Tris-HCl pH7.3 was prepared and used to prepare a series of dilutions from 0-100μM in 100mM Tris-HCl pH 7.3. 990μl of each dilution was placed in a quartz cuvette and pre-warmed to 37°C. 10μl of enzyme solution was added to initiate the reaction and the progress of the reaction was followed by measuring the rate of change in absorbance at 356nm. The change in extinction coefficient of Tomudex at 356nm following complete conversion of a 100μM solution by an excess of CPG_2 was measured in order to calculate the change in extinction coefficient due to the complete conversion

of 100nmol of Tomudex. With this data, measured rates can then be converted to values of μmol/min (V_{max}), and K_m and k_{cat} determined.

Measurement of the rate of reaction at a range of substrate concentrations, from 1-100μM allows the K_m and k_{cat} for the enzyme to be determined using appropriate computer software such as "Enzfitter" (Biosoft, Cambridge, UK). Results of the spectrophotometric assay showed that Tomudex is a substrate for CPG_2 having a K_m of 7.8μM and a K_{cat} of 24/s.

B: Edatrexate (Formula V)

Edatrexate is a DHFR inhibitor (Ciba Geigy). Edatrexate is contacted with CPG_2 *in vitro* and is found to be a substrate of CPG_2.

Deglutamylation of Edatrexate by CPG_2 is measured spectrophotometrically. A stock solution of 10mM Edatrexate in 100mM Tris-HCl pH7.3 is prepared and used to prepare a series of dilutions from 0-100μM in 100mM Tris-HCl pH 7.3. 990μl of each dilution is placed in a quartz cuvette and pre-warmed to 37°C. 10μl of enzyme solution is added to initiate the reaction and the progress of the reaction is followed by measuring the rate of change in absorbance at a suitable wavelength. The change in extinction coefficient of Edatrexate following complete conversion of a 100μM solution by an excess of CPG_2 is measured in order to calculate the change in extinction coefficient due to the complete conversion of 100nmol of Edatrexate. With this data, measured rates are converted to values of μmol/min. Measurement of the rate of reaction at a range of substrate concentrations, from 1-100μM allows the K_m and k_{cat} for the enzyme to be determined using Enzfitter computer software.

C: Lometrexol (Formula VI)

Lometrexol is a GARFT inhibitor (Tularik, originated Lilly). Lometrexol is contacted with CPG_2 *in vitro* and is found to be a substrate of CPG_2.

Deglutamylation of Lometrexol by CPG_2 is measured spectrophotometrically. A stock solution of 10mM Lometrexol in 100mM Tris-HCl pH7.3 is prepared and used to prepare a series of dilutions from 0-100μM in 100mM Tris-HCl pH 7.3. 990μl of each dilution is placed in a quartz cuvette and pre-warmed to 37°C. 10μl of enzyme solution is added to initiate the reaction and the progress of the reaction is followed by measuring the rate of change in absorbance at a suitable wavelength. The change in extinction coefficient of Lometrexol following complete conversion of a 100μM solution by an excess of CPG_2 is measured in order to calculate the change in extinction coefficient due to the complete conversion of 100nmol of Lometrexol. With this data, measured rates are converted to values of μmol/min. Measurement of the rate of reaction at a range of substrate concentrations, from 1-100μM allows the K_m and k_{cat} for the enzyme to be determined using Enzfitter computer software.

D: ZD9331 (Formula VII)

ZD9331 is a thymidilate synthase inhibitor (Astra Zeneca). ZD9331 is contacted with CPG_2 *in vitro* and is found to be a substrate of CPG_2.

Cleavage of ZD9331 by CPG_2 is measured spectrophotometrically. A stock solution of 10mM ZD9331 in 100mM Tris-HCl pH7.3 is prepared and used to prepare a series of dilutions from 0-100μM in 100mM Tris-HCl pH 7.3. 990μl of each dilution is placed in a quartz cuvette and pre-warmed to 37°C. 10μl of enzyme solution is added to initiate the reaction and the progress of the reaction is followed by measuring the rate of change in absorbance at a

suitable wavelength. The change in extinction coefficient of ZD9331 following complete conversion of a 100μM solution by an excess of CPG_2 is measured in order to calculate the change in extinction coefficient due to the complete conversion of 100nmol of ZD9331. With this data, measured rates are converted to values of μmol/min. Measurement of the rate of reaction at a range of substrate concentrations, from 1-100μM allows the K_m and k_{cat} for the enzyme to be determined using Enzfitter computer software.

E: MTA/Pemetrexed (Formula VIII)

MTA is a inhibitor of multiple loci of the thymidine synthesis pathway (Lilly). MTA is contacted with CPG_2 *in vitro* and is found to be a substrate of CPG_2.

Deglutamylation of MTA by CPG_2 is measured spectrophotometrically. A stock solution of 10mM MTA in 100mM Tris-HCl pH7.3 is prepared and used to prepare a series of dilutions from 0-100μM in 100mM Tris-HCl pH 7.3. 990μl of each dilution is placed in a quartz cuvette and pre-warmed to 37°C. 10μl of enzyme solution is added to initiate the reaction and the progress of the reaction is followed by measuring the rate of change in absorbance at a suitable wavelength. The change in extinction coefficient of MTA following complete conversion of a 100μM solution by an excess of CPG_2 is measured in order to calculate the change in extinction coefficient due to the complete conversion of 100nmol of MTA. With this data, measured rates are converted to values of μmol/min. Measurement of the rate of reaction at a range of substrate concentrations, from 1-100μM allows the K_m and k_{cat} for the enzyme to be determined using Enzfitter computer software.

F: MDAM (Formula IX)

MDAM is contacted with CPG_2 *in vitro* and is found to be a substrate of CPG_2.

Cleavage of MDAM by CPG_2 is measured spectrophotometrically. A stock solution of 10mM MDAM in 100mM Tris-HCl pH7.3 is prepared and used to prepare a series of dilutions from 0-100μM in 100mM Tris-HCl pH 7.3. 990μl of each dilution is placed in a quartz cuvette and pre-warmed to 37°C. 10μl of enzyme solution is added to initiate the reaction and the progress of the reaction is followed by measuring the rate of change in absorbance at a suitable wavelength. The change in extinction coefficient of MDAM following complete conversion of a 100μM solution by an excess of CPG_2 is measured in order to calculate the change in extinction coefficient due to the complete conversion of 100nmol of MDAM. With this data, measured rates are converted to values of μmol/min. Measurement of the rate of reaction at a range of substrate concentrations, from 1-100μM allows the K_m and k_{cat} for the enzyme to be determined using Enzfitter computer software.

Example 2: Rescue of Tomudex toxicity by administration of CPG_2

A patient who has been administered Tomudex and has toxic plasma levels of Tomudex is administered a dose of 50 Units per kg body weight of CPG_2 by intravenous injection over a period of about 5 minutes. The patient's plasma concentration of Tomudex is reduced to non-toxic levels.

Example 3: Rescue of Tomudex toxicity by administration of CPG_2 and thymidine

A patient who has been administered Tomudex and has toxic plasma levels of Tomudex is administered a dose of 50 Units per kg body weight of CPG_2 by intravenous injection over a period of about 5 minutes and is also

administered thymidine. The thymidine rescues the cellular toxicity associated with the Tomudex, while the CPG_2 drastically reduces the plasma concentration of Tomudex to non-toxic levels.

List of References

Adamson, PC *et al* (1991) "Rescue of experimental *intrathecal* methotrexate overdose with carboxypeptidase-G2." *J Clin Oncol* **9**: 670-674.

Bleyer, WA (1978) "The Clinical Pharmacology of Methotrexate. New applications for an old drug." *Cancer* **41**: 36-51.

Chabner, B *et al* (1972) "Enzymatic cleavage of methotrexate provides a method for prevention of drug toxicity." *Nature* **239**: 395-397.

Clarke SJ *et al* (2000) "Clinical and preclinical pharmacokinetics of raltitrexed." *Clin Pharmacokinet.* **39(6)**: 429-43.

Condit, P *et al* (1969) "Renal toxicity of methotrexate." *Cancer* **23**: 126-131.

Dowell, RI *et al* (1996) "New mustard prodrugs for antibody-directed enzyme prodrug therapy: alternatives to the amide link." *J. Med. Chem.* **39**: 1100-1105.

Dreicer R *et al* (1997) "A phase II trial of edatrexate in patients with advanced renal cell carcinoma. An Eastern Cooperative Oncology Group study." *Am J Clin Oncol.* **20(3)**: 251-3.

Ettinger DS. (2002) "Pemetrexed (alimta): a new antifolate for non-small-cell lung cancer." *Clin Lung Cancer* **3 Suppl 1**: S22-5.

Franchi F *et al*, (2003) "Favorable toxicity profile of raltitrexed in elderly patients treated for colorectal cancer: a case series."*Gerontology* **49(5)**: 324-7.

Goldman, I (1975) "Membrane transport of methotrexate and other folate compounds: relevance to rescue protocols." *Cancer Chemo Rep* **6**: 63-72.

Johansen M *et al*, (2003) "Final results of a phase I and pharmacokinetic study of gamma-methylene-10-deazaaminopterin (MDAM) administered intravenously daily for five consecutive days in patients with solid tumors. *Cancer Chemother Pharmacol.* Dec 18 [Epub ahead of print]

Jolivet, J *et al* (1983) "The pharmacology and clinical use of methotrexate." *N Engl J Med* **309**: 1094-1104.

Kalghatgi, K and Bertino J (1981) "Folate-degrading enzymes: a review with special emphasis on Carboxypeptidase G." *In: Enzymes as drugs* J Holcenberg and J Roberts, eds, Wiley, New York, pp 77-102.

Kintzel, PE (2001) "Anticancer drug-induced kidney disorders." *Drug Saf* **24**: 19-38.

Kisliuk RL (2003) "Deaza analogs of folic acid as antitumor agents." *Current Pharmaceutical Design* **9(31)**: 2615-2625.

Kuriakose P *et al*, (2002) "Phase I trial of edatrexate in advanced breast and other cancers." *Cancer Invest.* **20(4)**: 473-9.

Martin M *et al*, (2003) "Phase II study of pemetrexed in breast cancer patients pretreated with anthracyclines. *Ann Oncol.* **14(8)**: 1246-52.

Massacesi C *et al*, (2003) "Raltitrexed-induced hepatotoxicity: multivariate analysis of predictive factors." *Anticancer Drugs* **14(7)**: 533-41.

McCullough, J *et al* (1971) "Purification and properties of Carboxypeptidase G1." *J Biol Chem* **246**: 7207-7213.

McGuire JJ (2003) "Anticancer antifolates: current status and future directions" *Current Pharmaceutical Design* **9(31)**: 2593-2613.

Meyers, FJ *et al* (1998-99) "Phase II trial of edatrexate in relapsed or refractory germ cell tumors: a Southwest Oncology Group study (SWOG 9124). *Invest New Drugs*. **16(4)**: 347-51.

Minton, NP *et al* (1983) "Molecular cloning of the *Pseudomonas* Carboxypeptidase G2 gene and its expression in *Escherichia coli* and *Pseudomonasputida*." *J Bacteriol* **156**: 1222-1227.

Mohty, M *et al* (2000) "Carboxypeptidase G2 rescue in delayed methotrexate elimination in renal failure." *Leuk Lymphoma* **37**: 441-443.

Pinedo, H *et al* (1976) "The reversal of methotrexate cytotoxicity to mouse bone marrow cells by leucovorin and nucleosides." *Cancer Res* **36**: 4418-4424.

Pisters KM *et al*, (1996) "High-dose edatrexate with oral leucovorin rescue: a phase I and clinical pharmacological study in adults with advanced cancer." *Clin Cancer Res*. **2(11)**: 1819-24.

Purcell, WT & Ettinger DS (2003) "Novel antifolate drugs" *Current Oncology Reports* **5(2)**: 114-125.

Rowsell, S *et al* (1997) "Crystal structure of carboxypeptidase G2, a bacterial enzyme with applications in cancer therapy." *Structure* **5(3)**: 337-47.

Sherwood, RF *et al* (1985) "Purification and properties of Carboxypeptidase G2 from *Pseudomonas sp.* strain RS-16. Use of a novel triazine dye affinity method." *Eur J Biochem* **148**: 447-453.

Springer, CJ *et al* (1995) "Optimization of alkylating agent prodrugs derived from phenol and aniline mustards: a new clinical candidate prodrug (ZD2767) for antibody-directed enzyme prodrug therapy." *J. Med. Chem.* **38**: 5051-65.

Thodtmann, R *et al*, (2003) "A phase II trial of pemetrexed in patients with metastatic renal cancer." *Invest New Drugs* **21(3)**: 353-8.

Tsavaris, N *et al* (2002) "Raltitrexed (Tomudex) administration in patients with relapsed metastatic colorectal cancer after weekly irinotecan/5-Fluorouracil/Leucovorin chemotherapy." *BMC Cancer*. **2(1)**: 2. Epub 2002 Jan 30.

Von Poblozki, A *et al* (2000) "Carboxypeptidase-G2 rescue in a woman with methotrexate-induced renal failure." *Med Klin* **95**: 457-460.

Widemann, BC *et al* (2000) "Pharmacokinetics and metabolism of the methotrexate metabolite 2,4-diamino-N1o-methylpteroic acid." *J Pharmacol Expel Therapy* **294**: 894-901.

CLAIMS

1. A method of combating toxicity caused by an antifolate compound of Formula I,



I

wherein

R^1 represents NH_2, OH or CH_3;

R^2 represents NH_2 or C_{1-4} alkyl;

the group B represents a structural fragment of Formula Ia, Ib, Ic, Id or Ie,



Ia



Ib



Ic



Id



Ie

in which groups the dashed lines indicate the point of ring fusion with the pyrimidinyl ring and the wavy lines indicate the point of attachment of the structural fragments to the group X;

R^{5a} to R^{5e} independently represent H or C_{1-4} alkyl;

A^1 represents $C(R^{6a})$ or N;

A^2 represents CH or N;

A^3 represents $C(H)R^{6b}$, NR^{6c} or S;

A^4 and A^5 independently represent CH_2, NH, O or S;

the group B^1-B^2 represents CH-CH or C=C;

R^{6a} to R^{6c} independently represent H or C_{1-4} alkyl, or R^{6c} represents $C(O)R^{6d}$, or R^{6c}, together with R^{7b} represents C_{1-2} *n*-alkylene;

R^{6d} represents H or C_{1-4} alkyl;

X represents $-CH_2C(H)R^{7a}-$ or $-CH_2NR^{7b}-$ (in which latter two groups the CH_2 moiety is attached to the fused, pyrimidine-based heterocyclic group);

R^{7a} and R^{7b} independently represent H, C_{1-6} alkyl, C_{3-6} alkenyl or C_{3-6} alkynyl, or R^{7b}, together with R^{6c} represents C_{1-2} *n*-alkylene;

Ar represents a structural fragment of Formula IIa or IIb,



IIa



IIb

wherein the wavy lines indicate the points of attachment of the structural fragments;

A^6 represents O or S;

R^{8a} and R^{8b} independently represent H or one or two substituents selected from halo, C_{1-4} alkyl and C_{1-4} alkoxy or R^{8a}, together with R^3, when R^{8a} is attached at a position that is *ortho-* to the position to which the moiety $C(O)NR^3$ is attached, represents C_{1-2} *n*-alkylene;

R^3 represents H or C_{1-4} alkyl, or R^3, together with R^{8a}, when the latter group is attached at a position that is *ortho-* to the position to which the moiety $C(O)NR^3$ is attached, represents C_{1-2} *n*-alkylene;

R^4 represents $-CH_2C(R^{9a})(R^{9b})$-D;

R^{9a} and R^{9b} independently represent H or C_{1-4} alkyl, or R^{9a} and R^{9b} together represent $=C(H)R^{10}$;

R^{10} represents H or C_{1-4} alkyl;

D represents C(O)OH, tetrazol-5-yl, $(CH_2)_{0-1}$-NHR^{11}, or, when R^{9a} and R^{9b} together represent $=C(H)R^{10}$, then D may also represent H, or D represents a structural fragment of Formula IIIa or IIIb,



IIIa



IIIb ;

wherein the wavy lines indicate the point of attachment of the structural fragments;

R^{11} represents H or $C(O)R^{12}$;

R^{12} represents H or phenyl substituted by C(O)OH and optionally substituted by one or two further substituents selected from halo, C_{1-4} alkyl and C_{1-4} alkoxy; and

alkyl, alkenyl and alkynyl groups, as well as the alkyl part of alkoxy groups, may be substituted by one or more halo atoms;

provided that when R^2 represents NH_2, Ar represents a structural fragment of Formula IIa in which R^{8a} represents H, R^3 represents H, R^{9a} and R^{9b} both represent H and D represents C(O)OH, then:

(a) when R^{7b} represents methyl and R^1 represents NH_2, then B does not represent a structural fragment of Formula Ia in which R^{5a} represents H and A^1 and A^2 both represent N; and

(b) when R^{7b} represents H and R^1 represents OH, then B does not represent

(i) a structural fragment of Formula Ia in which R^{5a} represents H and A^1 and A^2 both represent N, or

(ii) a structural fragment of Formula Ic in which R^{5c} represents H, A^3 represents NR^{6c}, R^{6c} represents methyl or CHO and A^4 represents NH,

in an individual who has been administered said compound, the method comprising administering to the individual an enzyme that has carboxypeptidase G activity.

2. A method according to Claim 1 wherein the antifolate compound of Formula I is Tomudex, Edatrexate, Lometrexol, ZD9331, Pemetrexed or MDAM.

3. A method according to Claim 1 or 2 wherein the individual is administered the enzyme that has carboxypeptidase G activity between about 24 and 48 hours after being administered the antifolate compound.

4. A method according to any of Claims 1 to 3 wherein the individual has one of more clinical markers of toxicity caused by the antifolate compound.

5. A method according to Claim 4 wherein the clinical marker of toxicity caused by the antifolate compound is a plasma level of the compound greater than a predetermined level indicating toxicity at a given time after administration of the compound.

6. A method according to Claim 5 wherein the predetermined blood plasma level of the antifolate compound indicating toxicity is 1μM at 24 hours after administration of the compound.

7. A method according to Claim 5 or 6 further comprising the prior step of determining the plasma level of the antifolate compound in the individual at a given time after administration of the compound.

8. A method according to any of Claims 1 to 7 wherein the individual has one or more clinical symptoms of toxicity caused by the antifolate compound.

9. A method according to Claim 8 wherein the clinical symptom of toxicity caused by the antifolate compound is selected from anaemia, anorexia, asthenia, dehydration, diarrhoea, fatigue, fever, hepatotoxicity, hyperbilirubinaemia, leukopaenia, mucositis, myelosuppression, nausea, neutropaenia, rash, reversible transaminitis, stomatitis, thrombocytopaenia and vomiting.

10. A method according to Claim 8 or 9 further comprising the prior step of determining the presence of the one or more clinical symptoms of toxicity caused by the antifolate compound in the individual.

11. A method according to any of Claims 1 to 10 and further comprising administering a folate pathway rescue agent to the individual.

12. A method according to Claim 10 wherein the antifolate compound of Formula I is an inhibitor of dihydrofolate reductase (DHFR) or of

glycinamide ribonucleotide formyltransferase (GARFT), and the folate pathway rescue agent is leucovorin calcium.

13. A method according to Claim 12 wherein the antifolate compound is Edatrexate, Lometrexol or Pemetrexed.

14. A method according to Claim 13 wherein the antifolate compound of Formula I is an inhibitor of thymidylate synthase (TS), and the folate pathway rescue agent is thymidine.

15. A method according to Claim 14 wherein the antifolate compound is Tomudex, ZD9331 or Pemetrexed.

16. A method according to any of Claims 11 to 15 wherein the individual is administered the enzyme that has carboxypeptidase G activity prior to the folate pathway rescue agent.

17. A method according to any of Claims 11 to 15 wherein the individual is administered the folate pathway rescue agent prior to the enzyme that has carboxypeptidase G activity.

18. A method according to any of Claims 11 to 15 wherein the individual is administered the folate pathway rescue agent and the enzyme that has carboxypeptidase G activity substantially simultaneously.

19. A method according to any of Claims 1 to 18 wherein the individual is administered the enzyme that has carboxypeptidase G activity at a dose of about 50 Units per kg body weight.

20. A method of treating a disease selected from cancer, rheumatoid arthritis (RA), multiple sclerosis (MS), psoriasis, extrauterine pregnancy and graft vs. host disease comprising administering an antifolate compound of Formula I to the individual, and subsequently administering to the individual an enzyme that has carboxypeptidase G activity.

21. A method according to Claim 20 wherein the antifolate compound of Formula I is Tomudex and the cancer to be treated is cancer of the breast, ovary, colon/rectum, liver, prostate, pancreas or stomach, or non small cell lung cancer (NSCLC), malignant mesothelioma or carcinoma of unknown primary.

22. A method according to Claim 20 wherein the antifolate compound is Edatrexate and the cancer to be treated is breast cancer, lung cancer, head and neck cancer, squamous cell carcinoma, NSCLC, non-Hodgkin's lymphoma, germ cell tumour, pleural mesothelioma or malignant fibrous histiocytoma.

23. A method according to Claim 20 wherein the antifolate compound is ZD9331 and the cancer to be treated is ovarian cancer, colorectal cancer, gastric cancer, small cell lung cancer, fallopian tube cancer, primary peritoneal cancer or lymphoma.

24. A method according to Claim 20 wherein the antifolate compound is Pemetrexed and the cancer to be treated is leukemia, mesothelioma, NSCLC, breast, colon, pancreas, kidney, bladder, gastrointestinal cancer, head and neck cancer, urothelial cancer or cervical carcinoma.

25. A method according to Claim 20 wherein the antifolate compound is Lometrexol and the cancer to be treated is soft tissue sarcoma, NSCLC, breast cancer, head and neck cancer or melanoma.

26. Use of an enzyme that has carboxypeptidase G activity in the preparation of a medicament for combating toxicity caused by an antifolate compound of Formula I as defined in Claim 1 or Claim 2.

27. Use according to Claim 26 for combating toxicity in an individual who has one of more clinical markers of toxicity caused by the antifolate compound.

28. Use according to Claim 27 wherein the clinical marker of toxicity is a plasma level of the antifolate compound greater than a predetermined level indicating toxicity at a given time after administration of the compound.

29. Use according to Claim 28 wherein the predetermined plasma level of the antifolate compound indicating toxicity is 1μM at 24 hours after administration of the compound.

30. Use according to any of Claims 26 to 29 for combating toxicity in an individual who has one of more clinical symptoms of toxicity caused by the antifolate compound.

31. Use according to Claim 30 wherein the clinical symptom of toxicity caused by the antifolate compound is selected from anaemia, anorexia, asthenia, dehydration, diarrhoea, fatigue, fever, hepatotoxicity, hyperbilirubinaemia, leukopaenia, mucositis, myelosuppression, nausea,

neutropaenia, rash, reversible transaminitis, stomatitis, thrombocytopaenia and vomiting.

32. Use of an antifolate compound of Formula I as defined in Claim 1 or Claim 2 in the preparation of a medicament for combating a disease combatable by said antifolate compound in an individual who is subsequently administered an enzyme that has carboxypeptidase G activity.

33. Use according to any of Claims 26 to 32 for combating toxicity in an individual who is administered a folate pathway rescue agent.

34. Use according to Claim 33 wherein the individual is administered the folate pathway rescue agent prior to the enzyme that has carboxypeptidase G activity.

35. Use according to Claim 33 wherein the individual is administered the folate pathway rescue agent after the enzyme that has carboxypeptidase G activity.

36. Use according to Claim 33 wherein the individual is administered the folate pathway rescue agent and the enzyme that has carboxypeptidase G activity substantially simultaneously.

37. Use of a folate pathway rescue agent in the preparation of a medicament for combating toxicity caused by an antifolate compound of Formula I as defined in Claim 1 or Claim 2 in an individual who is administered an enzyme that has carboxypeptidase G activity.

38. Use of an enzyme that has carboxypeptidase G activity and a folate pathway rescue agent in the preparation of a medicament for combating toxicity caused by an antifolate compound of Formula I as defined in Claim 1 or Claim 2.

39. Use according to any of Claims 33 to 38 wherein the antifolate compound is an inhibitor of DHFR or GARFT, and the folate pathway rescue agent is leucovorin.

40. Use according to Claim 39 wherein the antifolate compound is Edatrexate, Lometrexol or Pemetrexed.

41. Use according to any of Claims 33 to 38 wherein the antifolate compound of Formula I is an inhibitor of TS, and the folate pathway rescue agent is thymidine.

42. Use according to Claim 41 wherein the antifolate compound of Formula I is Tomudex, ZD9331 or Pemetrexed.

43. Use according to any of Claims 26 to 42 wherein the enzyme that has carboxypeptidase G activity is at a dose of about 50 Units per kg body weight.

44. Use according to any of Claims 26 to 43 for combating toxicity caused by an antifolate compound of Formula I in an individual who is being treated for a disease selected from cancer, RA, MS, psoriasis, extrauterine pregnancy and graft vs. host disease by administration of the antifolate compound.

45. Use of an antifolate compound of Formula I as defined in Claim 1 or Claim 2 in the preparation of a medicament for treating a condition selected from cancer, RA, MS, psoriasis, extrauterine pregnancy and graft vs. host disease in an individual who is subsequently administered an enzyme that has carboxypeptidase G activity.

46. Use of an enzyme that has carboxypeptidase G activity in the preparation of a medicament for complementing the therapy of a disease selected from cancer, RA, MS, psoriasis, extrauterine pregnancy and graft vs. host disease that is being treated by administration of an antifolate compound of Formula I.

47. Use according to any of Claims 44 to 46 wherein the antifolate compound of Formula I and the cancer to be treated are as defined in any of Claims 21-25.

48. A therapeutic system comprising an antifolate compound of Formula I as defined above in Claim 1 or 2, and an enzyme that has carboxypeptidase G activity.

49. A therapeutic system according to Claim 48 further comprising a folate pathway rescue agent.

50. An *ex vivo* method of cleaving a terminal L-glutamate moiety from a compound of Formula I as defined in Claim 1 or Claim 2, the method comprising contacting the compound with an enzyme that has carboxypeptidase G activity.

51. A method of determining the rate and/or extent of cleavage of a compound of Formula I as defined in Claim 1 or Claim 2 by an enzyme that has carboxypeptidase G activity, the method comprising:

providing the compound of Formula I,

contacting the compound of Formula I with an enzyme that has carboxypeptidase G activity under conditions such that cleavage of the compound can occur, and

monitoring the rate and/or extent of cleavage of the compound of Formula I over time.

52. A method according to Claim 51 wherein the monitoring step comprises monitoring the amount and/or concentration of the compound of Formula I.

53. A method according to Claim 51 or 52 wherein the monitoring step comprises monitoring the amount and/or concentration of one or more break-down products of the compound of Formula I.

54. A method according to any of Claims 51 to 53 which is performed *ex vivo*.

55. A method according to any of Claims 51 to 53 which is performed *in vivo*.

56. A method according to Claim 55 further comprising determining whether an additional dose of the enzyme that has carboxypeptidase G activity is required in order reduce the amount of the compound of Formula I to a predetermined level.

57. A method according to Claim 55 or 56 further comprising contacting the compound of Formula I with an additional dose of the enzyme that has carboxypeptidase G activity under conditions such that cleavage of the compound can occur.

58. A method according to any of Claims 1 to 25 or 50 to 57, or a use according to any of Claims 26 to 47, or a therapeutic system according to Claim 48 or 49, wherein the enzyme that has carboxypeptidase G activity is carboxypeptidase G_2, or a derivative thereof which has carboxypeptidase G activity.

ABSTRACT

USE OF ENZYME

A method of combating toxicity caused by an antifolate compound of Formula I,



I

in an individual who has been administered the compound. The method comprises administering an enzyme that has carboxypeptidase G activity to the individual.

Figure 2